John Castle
@joccastle.bsky.social
Inventing & translating technologies for therapies. ML AI ‘omics & comp biology. Molecular glue for targeted protein degraders. MonteRosaTx. Tweets my own
We believe molecular glues represent a new horizon for small molecule drug development, and it’s thrilling to collaborate – yet again – with a recognized global leader in immune-mediated diseases. This validates the hard work our entire team has done redefining what is possible with molecular glues.
Today we announced our second collaboration with @novartis.bsky.social to develop novel degraders for immune-mediated diseases. Given the strong progress we’ve made on our collaboration advancing VAV1 degraders, we’re thrilled to be collaborating with them again: bit.ly/3Vl0yTg
September 15, 2025 at 11:49 AM
We believe molecular glues represent a new horizon for small molecule drug development, and it’s thrilling to collaborate – yet again – with a recognized global leader in immune-mediated diseases. This validates the hard work our entire team has done redefining what is possible with molecular glues.
Reposted by John Castle
Leveraging proprietary AI and ML approaches, our researchers have discovered a broad range of human proteins potentially accessible to cereblon (CRBN)-based degradation, spanning diverse protein domains and classes, including many targets historically considered undruggable.
July 7, 2025 at 12:25 PM
Leveraging proprietary AI and ML approaches, our researchers have discovered a broad range of human proteins potentially accessible to cereblon (CRBN)-based degradation, spanning diverse protein domains and classes, including many targets historically considered undruggable.
Reposted by John Castle
Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of Science Magazine, @science.org.
We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m
We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m
July 8, 2025 at 12:23 PM
Sharon Townson and John Castle comment on our groundbreaking work recently featured on the cover of Science Magazine, @science.org.
We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m
We’ve shown the molecular glue target space is broader than previously understood, and we believe we are uniquely positioned to harness its potential: bit.ly/4koxZ1m
PPI prediction is moving at breakneck speed! At @monterosatx.com, we’re pushing past nature’s playbook to chart new frontiers in drug discovery— integrating our cutting-edge PPI tools in the Queen Discovery Engine to degrade targets once thought undruggable.
Proud to share our invited review in @cp-trendsbiotech.bsky.social on using machine learning to predict de novo protein-protein interactions – pushing beyond nature’s blueprint to enable new advances in drug discovery and protein engineering.
Congrats to the team: bit.ly/3Zy4thY
Congrats to the team: bit.ly/3Zy4thY
May 27, 2025 at 1:12 PM
PPI prediction is moving at breakneck speed! At @monterosatx.com, we’re pushing past nature’s playbook to chart new frontiers in drug discovery— integrating our cutting-edge PPI tools in the Queen Discovery Engine to degrade targets once thought undruggable.
Great effort showing rational design going beyond canonical g-loops, enabling target expansion
May 2, 2025 at 3:34 PM
Great effort showing rational design going beyond canonical g-loops, enabling target expansion
Reposted by John Castle
Registration and abstract submission for the 22nd CIMT Annual Meeting are now open! Submit your abstract and present your research at #Europe'sCancerImmunotherapyMeeting in Mainz, Germany, May 12-14, 2025. www.meeting.cimt.eu
January 6, 2025 at 1:39 PM
Registration and abstract submission for the 22nd CIMT Annual Meeting are now open! Submit your abstract and present your research at #Europe'sCancerImmunotherapyMeeting in Mainz, Germany, May 12-14, 2025. www.meeting.cimt.eu
Reposted by John Castle
Good news: You can post video on Bluesky now!
Bad news: Only up to 60s.
So here’s a clipped version of my latest video about a paper exploring the landscape of possible molecular glue degradation targets:
Bad news: Only up to 60s.
So here’s a clipped version of my latest video about a paper exploring the landscape of possible molecular glue degradation targets:
November 20, 2024 at 2:22 AM
Good news: You can post video on Bluesky now!
Bad news: Only up to 60s.
So here’s a clipped version of my latest video about a paper exploring the landscape of possible molecular glue degradation targets:
Bad news: Only up to 60s.
So here’s a clipped version of my latest video about a paper exploring the landscape of possible molecular glue degradation targets:
Reposted by John Castle
Mark your calendars for the 22nd CIMT Annual Meeting in Mainz, Germany, May 12-14, 2025. Abstract submission and registration will open January 6. www.meeting.cimt.eu #cancerimmunotherapy
November 20, 2024 at 10:17 AM
Mark your calendars for the 22nd CIMT Annual Meeting in Mainz, Germany, May 12-14, 2025. Abstract submission and registration will open January 6. www.meeting.cimt.eu #cancerimmunotherapy
Reposted by John Castle
Novartis and Monte Rosa Therapeutics signed a deal to license the start-up’s VAV1 degrader MRT-6160 for possible use in immune conditions. The deal is just one in a series of molecular glue deals as Big Pharma eyes the growing field and the biotechs building it. cen.acs.org/pharmaceutic... #bluesci🧪
Big Pharma eyes a slew of molecular glues
The technology is quickly gaining adherents
cen.acs.org
November 18, 2024 at 10:30 PM
Novartis and Monte Rosa Therapeutics signed a deal to license the start-up’s VAV1 degrader MRT-6160 for possible use in immune conditions. The deal is just one in a series of molecular glue deals as Big Pharma eyes the growing field and the biotechs building it. cen.acs.org/pharmaceutic... #bluesci🧪